TG THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.19 USD | -1.40% |
|
+20.19% | -5.21% |
| May. 01 | Wall Street Set to Open Lower Ahead of Fed Rate Decision; Private Employment Figures Top Forecasts | MT |
| May. 01 | Transcript : TG Therapeutics, Inc., Q1 2024 Earnings Call, May 01, 2024 |
Financials (USD)
| Sales 2024 * | 309M | Sales 2025 * | 472M | Capitalization | 2.35B |
|---|---|---|---|---|---|
| Net income 2024 * | 12M | Net income 2025 * | 101M | EV / Sales 2024 * | 7.49 x |
| Net cash position 2024 * | 34.94M | Net cash position 2025 * | 128M | EV / Sales 2025 * | 4.7 x |
| P/E ratio 2024 * |
205
x | P/E ratio 2025 * |
25
x | Employees | 264 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.42% |
More Fundamentals
* Assessed data
More news
Latest transcript on TG Therapeutics, Inc.
More recommendations
More press releases
| 1 day | -1.40% | ||
| 1 week | +20.19% | ||
| Current month | +18.52% | ||
| 1 month | +11.89% | ||
| 3 months | -1.64% | ||
| 6 months | +46.38% | ||
| Current year | -5.21% |
1 week
12.93
18.00
1 month
12.9318.00
Current year
12.8422.67
1 year
6.4635.32
3 years
3.4842.31
5 years
3.4856.74
10 years
3.3256.74
| Managers | Title | Age | Since |
|---|---|---|---|
Michael Weiss
CEO | Chief Executive Officer | 58 | 93-05-17 |
Sean Power
DFI | Director of Finance/CFO | 42 | 11-12-28 |
Jenna A. Bosco
IRC | Investor Relations Contact | - | 11-11-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Michael Weiss
CEO | Chief Executive Officer | 58 | 93-05-17 |
Laurence Charney
BRD | Director/Board Member | 76 | 12-02-29 |
Kenneth Hoberman
BRD | Director/Board Member | 59 | 14-12-14 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.08% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-03 | 16.19 | -1.40% | 4,804,428 |
| 24-05-02 | 16.42 | +3.40% | 8,549,317 |
| 24-05-01 | 15.88 | +16.25% | 18,588,085 |
| 24-04-30 | 13.66 | +2.55% | 5,206,680 |
| 24-04-29 | 13.32 | -1.11% | 2,879,612 |
Delayed Quote Nasdaq, May 03, 2024 at 04:15 pm EDT
More quotes
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Brutonâs tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.
Calendar
2024-06-14
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
16.19
USD
Average target price
31.5
USD
Spread / Average Target
+94.56%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -5.21% | 2.35B | |
| +25.69% | 47.86B | |
| +46.90% | 41.42B | |
| -3.46% | 40.66B | |
| -6.20% | 28.92B | |
| +9.17% | 25.55B | |
| -20.42% | 19.27B | |
| +0.17% | 12.15B | |
| +28.07% | 12.14B | |
| -1.24% | 11.99B |
- Stock Market
- Equities
- TGTX Stock
